Belviq Breast Cancer Lawsuit Filed Over Side Effects of Recalled Diet Drug

Following a Belviq recall issued earlier, a number of product liability lawsuits are being filed by former users who say they developed cancer caused by side effects of the controversial diet drug.

In a complaint (PDF) filed this week in the U.S. District Court for the Eastern District of Louisiana, Stephanie Fuller indicates she was diagnosed with breast cancer last year, which she alleges was a direct result of exposure to Belviq.

Belviq and Belviq XR (lorcaserin) were introduced as prescription weight-loss treatments in 2012, amid serious questions about the safety and effectiveness of the drug. However, following aggressive marketing efforts by the drug maker, it quickly became widely used among individual attempting to lose weight.

Learn More About

Belviq Lawsuits

Side effects of Belviq may increase the risk of cancer, resulting in a diet drug recall and lawsuits.

Learn More About this Lawsuit See If You Qualify For Compensation

In February 2020, the FDA removed Belviq from the market after clinical trials identified a potential increased risk for several types of cancer, including pancreatic, colorectal and lung cancer. However, concerns emerged that side effects of Belviq may increase the risk of other tumors and injuries.

In the lawsuit filed on June 10, Fuller states she began taking the weight loss drug in August 2018, and continued using it through at least October 2018. However, in June 2019, she was diagnosed with breast cancer, which she claims was a direct result of the medication.

Fuller alleges that the drug manufacturers, Eisai Inc., and Arena Pharmaceuticals, recklessly made false and misleading representations about the risks associated with Belviq and failed to adequately research the potential side effects before marketing the diet drug.

“Defendants concealed their knowledge of Belviq’s defects, from Plaintiff, the FDA, the public in general, and/or the medical community specifically,” the lawsuit states. “These representations were made by Defendants with the intent of defrauding and deceiving Plaintiff, the public in general, and the medical and healthcare community in particular, and were made with the intent of inducing the public in general, and the medical community in particular, to recommend, dispense and/or purchase Belviq for chronic weight management, all of which evinced a callous, reckless, willful, depraved indifference to health, safety, and welfare of the Plaintiff herein.”

The case joins other Belviq lawsuits being pursued by individuals nationwide, including claims on behalf of former users who have been diagnosed with cancer, as well as class action claims for individuals who paid about $300 per month for the prescription and now face continuing health risks that require medical monitoring.

Since the strongest sales for Belviq have come over the past few years, it is widely expected that additional lawsuits will be filed in the coming weeks and months, as former users may be diagnosed with cases of breast cancer, pancreatic cancer, colorectal cancer, lung cancer and other injuries.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.